Drug Profile
Research programme: kidney disorder therapeutics - Bayer/Vanderbilt University Medical Center
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Bayer; Vanderbilt University Medical Center
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Kidney disorders
Highest Development Phases
- No development reported Kidney disorders
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for research development in Kidney-disorders in Germany
- 28 Oct 2021 No recent reports of development identified for research development in Kidney-disorders in USA
- 11 Sep 2017 Bayer and Vanderbilt University Medical Center agree to co-develop therapeutics for Kidney disorders